NRSN — Neurosense Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $29.80m
- $29.14m
Annual balance sheet for Neurosense Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.699 | 11.1 | 7.09 | 2.64 | 3.38 |
| Net Total Receivables | 0.03 | 0.178 | 0.131 | 0.166 | 0.902 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.729 | 11.4 | 7.38 | 2.92 | 4.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.013 | 0.019 | 0.306 | 0.247 | 0.15 |
| Other Long Term Assets | |||||
| Total Assets | 0.779 | 11.4 | 7.71 | 3.19 | 4.58 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.12 | 0.597 | 1.73 | 3.46 | 1.99 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.12 | 2.42 | 2.09 | 4.94 | 1.99 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 0.659 | 9.01 | 5.62 | -1.76 | 2.58 |
| Total Liabilities & Shareholders' Equity | 0.779 | 11.4 | 7.71 | 3.19 | 4.58 |
| Total Common Shares Outstanding |